Key result
An oral CVA16 vaccine using recombinant Lactococcus lactis significantly increased CVA16-specific IgG antibody levels compared to control (0.49 vs 0.05, p < 0.05) in mice.
Why the study?
The study was conducted to develop an oral vaccine against Coxsackievirus A16 by constructing a recombinant Lactococcus lactis expressing CVA16 VP1.
Absolute Event Rate: 0.49% vs 0.05%
p-value: p=<0.05
A recombinant Lactococcus lactis-based oral vaccine expressing CVA16 VP1 successfully elicited specific IgG and IgA antibody responses in a mouse model.
Supports preclinical oral CVA16 vaccine development; leaves open human immunogenicity and efficacy trials.
Purpose: To develop an oral vaccine against CVA16 (Coxsackievirus A16) by constructing a recombinant Lactococcus lactis that expresses VP1 from CVA16.Method: An oral CVA16 vaccine was prepared by expressing CVA16 VP1 protein with Lactococcus lactis. CVA16 VP1 gene was incorporated into a Lactobacillus expression vector, namely, pNZ8148, and then expressed in NZ9000, a food-grade lactic acid bacterium which serves as a carrier for oral vaccines.Results: There was statistically significant difference in CVA16-specific IgG antibody level between NZ9000-pNZ8148-CVA16-VP1 group (0.49 ± 0.05) and control group (0.05 ± 0.00) when the antiserum was diluted 1:10 (t = 19.84; p < 0.05). Furthermore, the level of CVA16-specific IgA antibody in NZ9000- pNZ8148-CVA16-VP1 group (0.17 ± 0.02) was significantly higher than in control group (0.05 ± 0.00) following antiserum dilution of 1:10 (t =12.08; p < 0.05).Conclusion: A CVA16 oral vaccine made from Lactobacillus elicits protective antibodies against CVA16. Thus, it is a potential as oral vaccine against CVA16 but further studies in vivo are required to ascertain its safety and effectiveness.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2020) studied Coxsackievirus A16 (CVA16) infection (n=10). Recombinant Lactococcus lactis NZ9000-pNZ8148-CVA16VP1 vs. Lactococcus lactis NZ9000-pNZ8148 (vector control) was evaluated on CVA16-specific IgG antibody level at 1:10 antiserum dilution (p=<0.05). An oral CVA16 vaccine using recombinant Lactococcus lactis significantly increased CVA16-specific IgG antibody levels compared to control (0.49 vs 0.05, p < 0.05) in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: